Patents by Inventor Alexander Flohr

Alexander Flohr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210252157
    Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.
    Type: Application
    Filed: January 8, 2021
    Publication date: August 19, 2021
    Inventors: Vijaya Raghavan PATTABIRAMAN, Roberto IACONE, Jean-Philippe CARRALOT, Matilde ARÉVALO-RUIZ, Jeffrey William BODE, Alexander MAYWEG, Fränzi WEIBEL, Anna HAYDN, Régis BOEHRINGER, Görkem KURTULDU SAHIN, Claudia FETZ, Camille DELON, Eric ARMENTANI, Alexander FLOHR, Giorgio OTTAVIANI
  • Patent number: 11034672
    Abstract: The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: June 15, 2021
    Assignee: Black Diamond Therapeutics, Inc.
    Inventors: Alexander Flohr, Alexander Mayweg, George Trainor, David M. Epstein, Matthew O'Connor, Elizabeth Buck, Luca Arista
  • Publication number: 20210163447
    Abstract: The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).
    Type: Application
    Filed: April 17, 2020
    Publication date: June 3, 2021
    Inventors: Alexander FLOHR, Alexander MAYWEG, George TRAINOR, David M. EPSTEIN, Matthew O'CONNOR, Elizabeth BUCK, Luca ARISTA
  • Patent number: 11021448
    Abstract: The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: June 1, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Alexander Flohr
  • Patent number: 10632127
    Abstract: The instant invention relates to novel conjugates of the compound of formula (I): S—L—A??(I) or salts thereof, wherein A is a ?-secretase inhibitor, L is a linker and S is a peptidase-specific substrate, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Alexander Flohr, Juillerat-Jeanneret Lucienne, Golshayan Dela
  • Publication number: 20200031848
    Abstract: The present invention provides compounds having Ar-V7 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of cancer.
    Type: Application
    Filed: December 18, 2017
    Publication date: January 30, 2020
    Inventors: Fuqiang BAN, Kush DALAL, Alexander FLOHR, Eric J. J. LEBLANC, Huifang LI, Paul S. RENNIE, Artem TCHERKASSOV
  • Patent number: 10399985
    Abstract: The present invention relates to compounds of formula I, wherein A, B, R1, R2, and Z are as defined hereinbefore.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 3, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden
  • Patent number: 10398702
    Abstract: The present invention provides a compound of formula I which act as inhibitors of SMAC protein binding to Inhibitor of Apoptosis Proteins (IAPs), and/or inhibitors of activated caspase protein binding to IAPs (I) their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, alone or in combination with DR5/FAP agonist antibodies. The active compound of the present invention is useful in the amelioration, treatment or control of cancer, especially solid tumors.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: September 3, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Guido Galley, Roger Norcross, Nicolas Zorn
  • Publication number: 20190256478
    Abstract: The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 22, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Alexander FLOHR
  • Publication number: 20190134050
    Abstract: The present invention provides a compound of formula I which act as inhibitors of SMAC protein binding to Inhibitor of Apoptosis Proteins (IAPs), and/or inhibitors of activated caspase protein binding to IAPs (I) their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, alone or in combination with DR5/FAP agonist antibodies. The active compound of the present invention is useful in the amelioration, treatment or control of cancer, especially solid tumors.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 9, 2019
    Inventors: Alexander FLOHR, Guido GALLEY, Roger NORCROSS, Nicolas ZORN
  • Publication number: 20180200262
    Abstract: The instant invention relates to novel conjugates of the compound of formula (I): S-L-A ??(I) or salts thereof, wherein A is a ?-secretase inhibitor, L is a linker and S is a peptidase-specific substrate, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Application
    Filed: December 11, 2017
    Publication date: July 19, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Alexander Flohr, Juillerat-Jeanneret Lucienne, Golshayan Dela
  • Patent number: 9932335
    Abstract: The present invention relates to compounds of formula wherein R1, Y1, Y2, X, R and n are as defined herein.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: April 3, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Theresa Maria Ballard, Emmanuel Pinard, Herve Schaffhauser, Katrin Groebke Zbinden, Thomas Ryckmans, Alexander Flohr
  • Patent number: 9617271
    Abstract: The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: April 11, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Christian Lerner
  • Patent number: 9586970
    Abstract: The present invention relates to compounds of formula (I), wherein A, B, R1 and R2 are as defined herein before useful for the treatment of psychiatric disorders.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: March 7, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Alexander Flohr
  • Patent number: 9540384
    Abstract: The invention relates to compounds of formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: January 10, 2017
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Matthias Koerner, Christian Lerner
  • Publication number: 20160333018
    Abstract: The present invention relates to compounds of formula I, wherein A, B, R1, R2, and Z are as defined hereinbefore.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 17, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden
  • Publication number: 20160264585
    Abstract: The present invention relates to compounds of formula (I), wherein A, B, R1 and R2 are as defined herein before useful for the treatment of psychiatric disorders.
    Type: Application
    Filed: May 24, 2016
    Publication date: September 15, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Alexander Flohr
  • Patent number: 9394311
    Abstract: The present invention provides compounds of formula (Ia) and (Ib) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: July 19, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Bernd Kuhn, Christian Lerner, Markus Rudolph, Herve Schaffhauser
  • Publication number: 20160194321
    Abstract: The present invention relates to compounds of formula wherein R1 halogen, lower alkyl, lower alkoxy, cyano, phenyl, C(O)NHCH3, C(O)NH2, lower alkyl substituted by halogen or is a five-membered heteroaryl group, optionally substituted by lower alkyl; Y1 is N or CH; Y2 is CH; and if Y1 is CH, Y1 and Y2 may form together with the C-atoms to which they are attached a ring, containing —CH?N—N(CH3)—, —CH?N—N(H)—; X is CH or N; R is (CH2)m-cycloalkyl, optionally substituted by hydroxy, lower alkoxy or lower alkyl, or is tetrahydropyran, optionally substituted by hydroxy, or is lower alkoxy, substituted by hydroxy, or is lower alkyl substituted by one or two hydroxy, or is (CH2)m-pyridinyl, optionally substituted by hydroxy, lower alkyl or lower alkyl substituted by hydroxy, or is L-phenyl, optionally substituted by hydroxy, lower alkyl or lower alkyl substituted by hydroxy, and L is a bond, —CH(CH2OH)— or —CH2CH(OH)—; n is 0, 1 or 2; m is 0 or 1; or to a pharmaceutically acceptable acid addition salt, to
    Type: Application
    Filed: March 11, 2016
    Publication date: July 7, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Theresa Maria BALLARD, Emmanuel PINARD, Herve SCHAFFHAUSER, Katrin GROEBKE ZBINDEN, Thomas RYCKMANS, Alexander FLOHR
  • Publication number: 20160031878
    Abstract: The present invention relates to radiolabeled compounds of formula I wherein R1, R2, R3 and R4 are as defined herein.
    Type: Application
    Filed: July 30, 2015
    Publication date: February 4, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Edilio BORRONI, Alexander FLOHR, Luca GOBBI, Thomas HARTUNG, Raphael HOAREAU, Michael HONER, Laurent MARTARELLO